GlassScriptPhysician profile
Jeffrey R Horvath
NPI 1588761811
$245,695.11
in general payments reported to CMS, 2019-2025
23 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $27K · 2021: $19K · 2022: $46K · 2023: $50K · 2024: $34K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Honoraria: $36K · Food and Beverage: $12K · Travel and Lodging: $5,558 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,550.00 |
| Honoraria | $36,135.00 |
| Food and Beverage | $12,421.54 |
| Travel and Lodging | $5,557.50 |
| Education | $218.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $88,206.90 | 2019-2025 | |
| Horizon Therapeutics Plc | $60,784.46 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $48,326.78 | 2019-2025 | |
| Amgen INC. | $39,417.80 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Ucb, INC. | $1,764.93 | 2019-2025 | Bimzelx, Cimzia |
| Histosonics, INC. | $1,723.31 | 2025 | |
| Bioventus LLC | $987.77 | 2019-2021 | |
| Pfizer INC. | $973.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $785.64 | 2022-2025 | Saphnelo |
| Lilly USA, LLC | $445.50 | 2019-2023 | Taltz |
| Janssen Biotech, INC. | $372.17 | 2022-2025 | Tremfya |
| Genzyme Corporation | $372.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $325.28 | 2019-2024 | Orencia |
| Genentech USA, INC. | $325.06 | 2019-2023 | Actemra |
| Sandoz INC. | $204.05 | 2023-2025 | Hyrimoz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $179.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.90 | 2023-2024 | Cyltezo |
| Aurinia Pharma U.S., INC. | $110.23 | 2022-2023 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $105.87 | 2019 | |
| Fresenius Kabi USA, LLC | $81.73 | 2023-2025 | Idacio, Tyenne |
| Pacira Therapeutics, INC. | $17.32 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $14.34 | 2023 | Iovera |
| Glaxosmithkline, LLC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Horvath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.